Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Evaluation of Cetuximab (C225) Combined With Induction Paclitaxel and Carboplatin Followed by C225, Paclitaxel, Carboplatin, and Radiation for Stage III/IV Operable Squamous Cancer of the Head and Neck

NCT00089297 is registered in ClinicalTrials.gov with Eastern Cooperative Oncology Group as lead sponsor.

NCT NCT00089297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00089297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Evaluation of Cetuximab (C225) Combined With Induction Paclitaxel and Carboplatin Followed by C225, Paclitaxel, Carboplatin, and Radiation for Stage III/IV Operable Squamous Cancer of the Head and Neck
Lead sponsor
Eastern Cooperative Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
January 6, 2005
Completion date
February 28, 2011
Enrollment
74 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer